Vandana Singh
·
September 8, 2025
Benzinga
Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.
read more
November 8, 2025
September 5, 2025
August 26, 2025
Barchart
August 12, 2025
Bloomberg
August 22, 2025